Table 1 Demographic data. Data is presented as median (range) or number (percentage). C carboplatin, P paclitaxel, B bevacizumab
Clinical data | Immunofluorescence biomarker study (n = 178) | Genotyping biomarker study (N = 449) | ICON7 population (N = 1528) | |||
|---|---|---|---|---|---|---|
C+P (N = 91) | C+P+B (N = 87) | C+P (N = 216) | C+P+B (N = 233) | C+P (N = 764) | C+P+B (N = 764) | |
Age, years | 58 (35–76) | 56 (25–75) | 58 (24–79) | 56 (24–77) | 57 (18–81) | 57 (24–82) |
ECOG performance status | ||||||
 0 | 32 (35) | 38 (44) | 87 (40) | 105 (45) | 358 (47) | 334 (44) |
 1 | 52 (57) | 45 (52) | 111 (51) | 117 (50) | 354 (47) | 366 (48) |
 2 | 2 (2) | 2 (2) | 13 (6) | 7 (3) | 43 (6) | 45 (6) |
 Unknown | 5 (5) | 2 (2) | 5 (2) | 4 (2) | 9 (1) | 19 (2) |
Histological subtype | ||||||
 Serous | 61 (67) | 56 (64) | 148 (69) | 158 (68) | 529 (69) | 525 (69) |
 Mucinous | 0 | 1 (1) | 3 (1) | 2 (1) | 15 (2) | 19 (2) |
 Endometrioid | 8 (9) | 4 (5) | 17 (8) | 15 (6) | 57 (7) | 60 (8) |
 Clear cell | 14 (15) | 15 (16) | 23 (11) | 30 (13) | 60 (8) | 67 (9) |
 Mixed | 5 (5) | 10 (11) | 13 (6) | 21 (9) | 48 (6) | 50 (5) |
 Others | 3 (3) | 1 (1) | 12 (6) | 7 (3) | 55 (7) | 53 (7) |
Histological grade | ||||||
 1 (well differentiated) | 2 (2) | 2 (2) | 10 (5) | 12 (5) | 57 (7) | 41 (5) |
 2 (moderately differentiated) | 13 (14) | 11 (13) | 34 (16) | 39 (17) | 142 (19) | 175 (23) |
 3 (poorly differentiated) | 76 (84) | 73 (84) | 169 (78) | 179 (77) | 556 (74) | 538 (71) |
 Unknown | 0 | 1 (1) | 3 (1) | 3 (1) | 10 | 10 |
FIGO (1988) stage | ||||||
 I/II | 17 (19) | 22 (25) | 46 (21) | 44 (19) | 145 (19) | 137 (18) |
 III/IV | 74 (81) | 65 (75) | 170 (79) | 189 (81) | 619 (81) | 627 (82) |
Debulking surgery | ||||||
 > 1 cm residual disease | 35 (38) | 26 (30) | 62 (29) | 61 (26) | 195 (26) | 192 (26) |
 ≤ 1 cm residual disease | 56 (62) | 61 (70) | 143 (71) | 167 (74) | 569 (76) | 572 (76) |